Media ReleasesLBT Innovations

View All LBT Innovations News

LBT Innovations - Quarterly Activities/Appendix 4C Cash Flow Report

Adelaide, Australia, 23 January 2023: Australian medical technology company LBT Innovations Limited (ASX: LBT) (LBT or the Company), a leader in medical technology automation using artificial intelligence, is pleased to release its Appendix 4C – Quarterly Cashflow report and business update for the quarter ended 31 December 2022 (the Quarter). All financial results are in Australian dollars and are unaudited.

Key Highlights

-- Over $3.0 million non-dilutive funding secured for strategic product development
-- NEW $10bn pharmaceutical microbial quality control testing market for APAS® Pharma
---- APAS® Pharma product development initiated with AstraZeneca and Thermo Fisher
---- LBT retains IP and commercialisation rights
-- EU go-to-market sales outlook improved
---- Thermo Fisher become exclusive EU distributor for APAS® Independence
---- Expanded total addressable market to 34 countries across Europe
-- $0.5 million raised from eligible shareholders through LBT Entitlement Offer
-- 31 December 2022 cash balance of $2.5 million plus $1.0 million in near term receivables

For more information, download the attached PDF.

Download this document

Subscribe to our Daily Newsletter?

Would you like to receive our daily news to your inbox?